Free Trial

Marpai (MRAI) Competitors

$0.75
+0.02 (+2.74%)
(As of 07/12/2024 ET)

MRAI vs. BRTX, OTRK, MGRX, GBNHF, CORBF, SGRP, CCRC, SREV, CLOV, and DVA

Should you be buying Marpai stock or one of its competitors? The main competitors of Marpai include BioRestorative Therapies (BRTX), Ontrak (OTRK), Mangoceuticals (MGRX), Greenbrook TMS (GBNHF), Global Cord Blood (CORBF), SPAR Group (SGRP), China Customer Relations Centers (CCRC), ServiceSource International (SREV), Clover Health Investments (CLOV), and DaVita (DVA).

Marpai vs.

BioRestorative Therapies (NASDAQ:BRTX) and Marpai (NASDAQ:MRAI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

In the previous week, BioRestorative Therapies had 3 more articles in the media than Marpai. MarketBeat recorded 3 mentions for BioRestorative Therapies and 0 mentions for Marpai. Marpai's average media sentiment score of 1.59 beat BioRestorative Therapies' score of 0.00 indicating that BioRestorative Therapies is being referred to more favorably in the media.

Company Overall Sentiment
BioRestorative Therapies Very Positive
Marpai Neutral

BioRestorative Therapies has a beta of 63.43, meaning that its stock price is 6,243% more volatile than the S&P 500. Comparatively, Marpai has a beta of 4.87, meaning that its stock price is 387% more volatile than the S&P 500.

Marpai received 1 more outperform votes than BioRestorative Therapies when rated by MarketBeat users. However, 100.00% of users gave BioRestorative Therapies an outperform vote while only 66.67% of users gave Marpai an outperform vote.

CompanyUnderperformOutperform
BioRestorative TherapiesOutperform Votes
1
100.00%
Underperform Votes
No Votes
MarpaiOutperform Votes
2
66.67%
Underperform Votes
1
33.33%

69.4% of BioRestorative Therapies shares are held by institutional investors. Comparatively, 49.8% of Marpai shares are held by institutional investors. 21.6% of BioRestorative Therapies shares are held by insiders. Comparatively, 61.3% of Marpai shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

BioRestorative Therapies has higher earnings, but lower revenue than Marpai. BioRestorative Therapies is trading at a lower price-to-earnings ratio than Marpai, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioRestorative Therapies$150K78.98-$14.41M-$2.31-0.76
Marpai$37.15M0.22-$28.75M-$3.19-0.24

Marpai has a net margin of -69.48% compared to Marpai's net margin of -7,303.33%. BioRestorative Therapies' return on equity of 0.00% beat Marpai's return on equity.

Company Net Margins Return on Equity Return on Assets
BioRestorative Therapies-7,303.33% -96.09% -85.36%
Marpai -69.48%N/A -68.67%

BioRestorative Therapies presently has a consensus price target of $15.00, indicating a potential upside of 757.14%. Marpai has a consensus price target of $6.00, indicating a potential upside of 700.05%. Given Marpai's higher probable upside, research analysts clearly believe BioRestorative Therapies is more favorable than Marpai.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioRestorative Therapies
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Marpai
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

BioRestorative Therapies beats Marpai on 9 of the 16 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MRAI vs. The Competition

MetricMarpaihealth & allied services, not elsewhere classified IndustryBusiness SectorNASDAQ Exchange
Market Cap$8.05M$2.21B$6.89B$8.66B
Dividend YieldN/A2.23%2.51%4.05%
P/E Ratio-0.2413.9315.2413.61
Price / Sales0.228.021,139.7381.34
Price / CashN/A11.3125.8632.70
Price / Book-0.443.814.454.46
Net Income-$28.75M$74.19M$122.13M$215.59M
7 Day Performance-3.85%4.42%2.88%5.37%
1 Month Performance-8.54%-1.20%1.36%3.37%
1 Year Performance-54.55%-25.77%-0.56%0.94%

Marpai Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BRTX
BioRestorative Therapies
3.9032 of 5 stars
3.90 / 5 stars
$1.80
-4.8%
$15.00
+733.3%
N/A$12.19M$150,000.00-0.7811Short Interest ↓
Positive News
OTRK
Ontrak
1.9737 of 5 stars
1.97 / 5 stars
$0.23
+4.6%
$4.00
+1,665.2%
-91.4%$10.22M$12.74M-0.06102Short Interest ↑
MGRX
Mangoceuticals
0.9354 of 5 stars
0.94 / 5 stars
$0.33
-8.5%
N/A-78.5%$8.84M$730,000.000.003Short Interest ↓
News Coverage
Gap Down
GBNHF
Greenbrook TMS
0 of 5 stars
0.00 / 5 stars
$0.06
-14.3%
N/AN/A$2.86M$73.79M0.00489News Coverage
CORBF
Global Cord Blood
0 of 5 stars
0.00 / 5 stars
$1.20
+9.1%
N/A+6.2%$0.00$196.12M0.001,202Gap Up
High Trading Volume
SGRP
SPAR Group
2.5115 of 5 stars
2.51 / 5 stars
$2.20
-1.8%
N/A+72.8%$54.51M$262.75M5.3724,288Short Interest ↑
CCRC
China Customer Relations Centers
0 of 5 stars
0.00 / 5 stars
$6.50
flat
N/A+0.0%$119.15M$240.32M0.0021,242
SREV
ServiceSource International
0 of 5 stars
0.00 / 5 stars
$1.50
flat
N/A+0.0%$150.39M$195.70M-16.662,900Analyst Forecast
CLOV
Clover Health Investments
0.468 of 5 stars
0.47 / 5 stars
$1.34
+0.8%
$1.50
+11.9%
+64.1%$660.26M$2.03B-3.94552
DVA
DaVita
3.529 of 5 stars
3.53 / 5 stars
$137.92
+0.4%
$144.67
+4.9%
+35.8%$12.05B$12.14B15.6770,000Short Interest ↓
Positive News

Related Companies and Tools

This page (NASDAQ:MRAI) was last updated on 7/13/2024 by MarketBeat.com Staff

From Our Partners